[Chemotherapy with low-dose docetaxel and estramustine phosphate in patient with liver dysfunction due to liver metastases of hormone-refractory prostate cancer : a case report].
A 82-year-old man was referred to our hospital for treatment of hormone-refractory prostate cancer with liver metastases. The obstruction of intrahepatic bile ducts due to the rapid growth of liver metastases induced liver dysfunction. We administered 25 mg/m(2) docetaxel on day1 and 280 mg/body estramustine phosphate on day 1 to day 3, every 4 weeks. After two courses of this combined chemothrapy, the liver metastases were markedly reduced in size with the rapid improvement of liver function.
Miyake
Miki
M
The Department of Urology, Yokohama City University Graduate School of Medicine.
Nakaigawa
Noboru
N
Kita
Kaoru
K
Yanagisawa
Masahiro
M
Terao
Hideyuki
H
Sano
Futoshi
F
Murakami
Takayuki
T
Makiyama
Kazuhide
K
Ogawa
Takehiko
T
Uemura
Hiroji
H
Yao
Masahiro
M
Kubota
Yoshinobu
Y
D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000077143:Docetaxel; D004961:Estramustine / Q000008:administration & dosage; D006801:Humans; D008107:Liver Diseases / Q000188:drug therapy / Q000209:etiology; D008113:Liver Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000556:secondary*; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D043823:Taxoids / Q000008:administration & dosage
D000970:Antineoplastic Agents; D018906:Antineoplastic Agents, Alkylating; D043823:Taxoids; D000077143:Docetaxel; D004961:Estramustine